Hydroxychloroquine for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Treatment of recurrent oligometastatic prostate cancer may be enhanced by the addition of Hydroxychloroquine to the current treatment regimens. Potential benefits of Hydroxychloroquine include delayed disease progression and delayed initiation of androgen deprivation therapy (ADT), thus lessening morbidity, distressing side effects, and improving functioning and quality of life in men with recurrent prostate cancer.Building on prior research at Markey, patients recently diagnosed with recurrent oligometastatic prostate cancer will be approached about participating in this study. Per standard of care, these patients undergo either surgery or radiation, in addition participants of this clinical trial will also receive Hydroxychloroquine (400 mg per day, oral medication) for 3 months.It is expected that a participant will exhibit a 50% increase of tumor suppressor PAR-4, as well as few, if any, negative side effects from Hydroxychloroquine.
Who Is on the Research Team?
Patrick J Hensley, MD
Principal Investigator
University of Kentucky
Peng Wang, MD
Principal Investigator
University of Kentucky
Are You a Good Fit for This Trial?
Men with recurrent oligometastatic prostate cancer, who have had surgery or radiation, can join this trial. They should have three or fewer metastatic lesions and no local disease left. Participants must be able to consent, perform daily activities (ECOG 0-2), and pass an eye exam. Those with allergies to similar drugs, severe eye conditions, prior HCQ use within 6 months, brain metastases, or on ADT are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 400 mg of Hydroxychloroquine per day for 3 months, in addition to standard care treatment of either surgical resection or stereotactic radiation
Follow-up
Participants are monitored for safety, effectiveness, and quality of life after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Hydroxychloroquine
Hydroxychloroquine is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Patrick Hensley
Lead Sponsor
Andrew C. James, MD
Lead Sponsor